Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) FCF Margin (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed FCF Margin for 12 consecutive years, with 19.74% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 9425.0% year-over-year to 19.74%, compared with a TTM value of 117.17% through Sep 2025, up 13417.0%, and an annual FY2024 reading of 190.6%, up 15288.0% over the prior year.
  • FCF Margin was 19.74% for Q3 2025 at Arcadia Biosciences, up from 139.73% in the prior quarter.
  • Across five years, FCF Margin topped out at 834.41% in Q3 2022 and bottomed at 627.05% in Q1 2021.
  • Average FCF Margin over 5 years is 184.38%, with a median of 179.59% recorded in 2024.
  • The sharpest move saw FCF Margin soared 262473bps in 2021, then plummeted -105667bps in 2023.
  • Year by year, FCF Margin stood at 157.67% in 2021, then surged by 126bps to 40.98% in 2022, then crashed by -1402bps to 533.46% in 2023, then skyrocketed by 66bps to 179.59% in 2024, then soared by 89bps to 19.74% in 2025.
  • Business Quant data shows FCF Margin for RKDA at 19.74% in Q3 2025, 139.73% in Q2 2025, and 132.33% in Q1 2025.